Literature DB >> 27062254

A key role for galectin-1 in sprouting angiogenesis revealed by novel rationally designed antibodies.

Judy R van Beijnum1, Victor L Thijssen1, Tilman Läppchen2,3, Tse J Wong1, Iris Verel2, Maurits Engbersen1, Iris A Schulkens1, Raffaella Rossin2, Holger Grüll2, Arjan W Griffioen1, Patrycja Nowak-Sliwinska1.   

Abstract

Galectins are carbohydrate binding proteins that function in many key cellular processes. We have previously demonstrated that galectins are essential for tumor angiogenesis and their expression is associated with disease progression. Targeting galectins is therefore a potential anti-angiogenic and anti-cancer strategy. Here, we used a rational approach to generate antibodies against a specific member of this conserved protein family, i.e. galectin-1. We characterized two novel mouse monoclonal antibodies that specifically react with galectin-1 in human, mouse and chicken. We demonstrate that these antibodies are excellent tools to study galectin-1 expression and function in a broad array of biological systems. In a potential diagnostic application, radiolabeled antibodies showed specific targeting of galectin-1 positive tumors. In a therapeutic setting, the antibodies inhibited sprouting angiogenesis in vitro and in vivo, underscoring the key function of galectin-1 in this process.
© 2016 UICC.

Entities:  

Keywords:  angiogenesis; antibody; galectin-1; imaging; sprouting; therapy

Mesh:

Substances:

Year:  2016        PMID: 27062254     DOI: 10.1002/ijc.30131

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  12 in total

Review 1.  Consensus guidelines for the use and interpretation of angiogenesis assays.

Authors:  Patrycja Nowak-Sliwinska; Kari Alitalo; Elizabeth Allen; Andrey Anisimov; Alfred C Aplin; Robert Auerbach; Hellmut G Augustin; David O Bates; Judy R van Beijnum; R Hugh F Bender; Gabriele Bergers; Andreas Bikfalvi; Joyce Bischoff; Barbara C Böck; Peter C Brooks; Federico Bussolino; Bertan Cakir; Peter Carmeliet; Daniel Castranova; Anca M Cimpean; Ondine Cleaver; George Coukos; George E Davis; Michele De Palma; Anna Dimberg; Ruud P M Dings; Valentin Djonov; Andrew C Dudley; Neil P Dufton; Sarah-Maria Fendt; Napoleone Ferrara; Marcus Fruttiger; Dai Fukumura; Bart Ghesquière; Yan Gong; Robert J Griffin; Adrian L Harris; Christopher C W Hughes; Nan W Hultgren; M Luisa Iruela-Arispe; Melita Irving; Rakesh K Jain; Raghu Kalluri; Joanna Kalucka; Robert S Kerbel; Jan Kitajewski; Ingeborg Klaassen; Hynda K Kleinmann; Pieter Koolwijk; Elisabeth Kuczynski; Brenda R Kwak; Koen Marien; Juan M Melero-Martin; Lance L Munn; Roberto F Nicosia; Agnes Noel; Jussi Nurro; Anna-Karin Olsson; Tatiana V Petrova; Kristian Pietras; Roberto Pili; Jeffrey W Pollard; Mark J Post; Paul H A Quax; Gabriel A Rabinovich; Marius Raica; Anna M Randi; Domenico Ribatti; Curzio Ruegg; Reinier O Schlingemann; Stefan Schulte-Merker; Lois E H Smith; Jonathan W Song; Steven A Stacker; Jimmy Stalin; Amber N Stratman; Maureen Van de Velde; Victor W M van Hinsbergh; Peter B Vermeulen; Johannes Waltenberger; Brant M Weinstein; Hong Xin; Bahar Yetkin-Arik; Seppo Yla-Herttuala; Mervin C Yoder; Arjan W Griffioen
Journal:  Angiogenesis       Date:  2018-08       Impact factor: 9.596

Review 2.  Regulation of wound healing and fibrosis by galectins.

Authors:  Dong Yu; Ming Bu; Ping Yu; Yaping Li; Yang Chong
Journal:  J Mol Med (Berl)       Date:  2022-05-19       Impact factor: 4.599

3.  Characterization of a neutralizing anti-human galectin-1 monoclonal antibody with angioregulatory and immunomodulatory activities.

Authors:  Juan M Pérez Sáez; Pablo F Hockl; Alejando J Cagnoni; Santiago P Méndez Huergo; Pablo A García; Sabrina G Gatto; Juan P Cerliani; Diego O Croci; Gabriel A Rabinovich
Journal:  Angiogenesis       Date:  2020-10-01       Impact factor: 9.596

4.  Vaccination against galectin-1 promotes cytotoxic T-cell infiltration in melanoma and reduces tumor burden.

Authors:  Julia Femel; Luuk van Hooren; Melanie Herre; Jessica Cedervall; Falk Saupe; Elisabeth J M Huijbers; Danielle R J Verboogen; Matthias Reichel; Victor L Thijssen; Arjan W Griffioen; Lars Hellman; Anna Dimberg; Anna-Karin Olsson
Journal:  Cancer Immunol Immunother       Date:  2022-01-11       Impact factor: 6.630

Review 5.  The clinical application of angiostatic therapy in combination with radiotherapy: past, present, future.

Authors:  Lisanne C Hamming; Ben J Slotman; Henk M W Verheul; Victor L Thijssen
Journal:  Angiogenesis       Date:  2017-03-31       Impact factor: 9.596

Review 6.  The complexity of tumour angiogenesis based on recently described molecules.

Authors:  Weronika Wiśniewska; Michał Kopka; Karolina Siemiątkowska; Marta Magdalena Fudalej; Aleksandra Sobiborowicz; Anna Maria Badowska-Kozakiewicz
Journal:  Contemp Oncol (Pozn)       Date:  2021-04-15

Review 7.  Viral-Vector-Delivered Anti-Angiogenic Therapies to the Eye.

Authors:  Sanna Koponen; Emmi Kokki; Kati Kinnunen; Seppo Ylä-Herttuala
Journal:  Pharmaceutics       Date:  2021-02-05       Impact factor: 6.321

8.  Treatment of B-cell precursor acute lymphoblastic leukemia with the Galectin-1 inhibitor PTX008.

Authors:  Helicia Paz; Eun Ji Joo; Chih-Hsing Chou; Fei Fei; Kevin H Mayo; Hisham Abdel-Azim; Haike Ghazarian; John Groffen; Nora Heisterkamp
Journal:  J Exp Clin Cancer Res       Date:  2018-03-27

9.  Nuclear FAM289-Galectin-1 interaction controls FAM289-mediated tumor promotion in malignant glioma.

Authors:  Xing Rong Guo; Mu Yu Wu; Long Jun Dai; Yu Huang; Meng Ye Shan; Shi Nan Ma; Jue Wang; Hao Peng; Yan Ding; Qiu Fang Zhang; Jun Ming Tang; Xu Zhi Ruan; Dong Sheng Li
Journal:  J Exp Clin Cancer Res       Date:  2019-09-06

10.  Oncogenes overexpressed in metastatic oral cancers from patients with pain: potential pain mediators released in exosomes.

Authors:  Aditi Bhattacharya; Malvin N Janal; Ratna Veeramachaneni; Igor Dolgalev; Zinaida Dubeykovskaya; Nguyen Huu Tu; Hyesung Kim; Susanna Zhang; Angie K Wu; Mari Hagiwara; A Ross Kerr; Mark D DeLacure; Brian L Schmidt; Donna G Albertson
Journal:  Sci Rep       Date:  2020-09-07       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.